Loading
CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes affected pathway 0.76, literature 0.94, genetic association 0.22, somatic mutation 0.80, animal model 0.76). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Burkitt Lymphoma, High-Grade Glioma, NOS, Low-Grade Glioma, NOS.
In plain words · CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.
No product in this corpus aims at CDKN2C yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1994. Earliest sequence paper UniProt cites for the protein: Guan K.-L. et al, Genes Dev, 1994, "Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function". Source.
Sources: HGNC HGNC:1789 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42773 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000123080 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: brain cancer 0.50 (GraphQL API, CC0)); IntOGen CDKN2C (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB. Locus 1p32.3 (HGNC).
Query for this target: (TITLE:"CDKN2C" OR ABSTRACT:"CDKN2C" OR TITLE:"cyclin dependent kinase inhibitor 2C" OR ABSTRACT:"cyclin dependent kinase inhibitor 2C" OR TITLE:"Cyclin-dependent kinase 4 inhibitor C" OR ABSTRACT:"Cyclin-dependent kinase 4 inhibitor C" OR TITLE:"INK4C" OR ABSTRACT:"INK4C" OR TITLE:"p18" OR ABSTRACT:"p18") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN2C, not a curated reading list.
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.
Shares Burkitt lymphoma, IntOGen.
Shares Burkitt lymphoma, IntOGen.
Shares Burkitt lymphoma, Open Targets Platform.
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.
Shares Burkitt lymphoma, IntOGen.
Shares Burkitt lymphoma, IntOGen.
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.